<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385398</url>
  </required_header>
  <id_info>
    <org_study_id>030601</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>0220060108</secondary_id>
    <secondary_id>CINJ-NJ1506</secondary_id>
    <secondary_id>CDR0000539474</secondary_id>
    <nct_id>NCT00385398</nct_id>
  </id_info>
  <brief_title>QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC</brief_title>
  <official_title>Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function&#xD;
      (the ability to think, learn, remember, and judge) in patients with non-small cell lung&#xD;
      cancer and brain metastases. A study that evaluates brain function may help doctors plan the&#xD;
      best treatment.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the effect of radiosurgery, temozolomide, and&#xD;
      erlotinib on brain function in patients with non-small cell lung cancer and brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effect of stereotactic radiosurgery, temozolomide, and erlotinib&#xD;
           hydrochloride on cognitive function in patients with non-small cell lung cancer and&#xD;
           brain metastases.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the feasibility and safety of this regimen, in terms of tumor response, time&#xD;
           to tumor progression in brain, survival, physical functioning, and quality of life, in&#xD;
           these patients.&#xD;
&#xD;
        -  Determine the frequency of O6-methylguanine-DNA methyltransferase promoter methylation&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo stereotactic radiosurgery on day -7. Patients receive oral temozolomide once&#xD;
      daily on days 1-5 and oral erlotinib hydrochloride once daily on days 1-23. Treatment with&#xD;
      temozolomide and erlotinib hydrochloride repeats every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo cognitive function evaluation as measured by Mini-Mental Status Exam&#xD;
      administration and scoring; quality of life assessment as measured by Functional Assessment&#xD;
      of Cancer Therapy subscale; and physical functioning assessment as measured by Katz index of&#xD;
      activities of daily living and Karnofsky performance status at baseline and then every 8&#xD;
      weeks during study treatment.&#xD;
&#xD;
      Tumor tissue is examined by O6-methylguanine-DNA methyltransferase (MGMT gene) promotor&#xD;
      methylation.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding and drug supply&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression in brain</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by FACT subscale</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning as measured by Karnofsky performance status and Katz index of activities of daily living</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of O6-methylguanine-DNA methyltransferase promoter methylation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <description>Stereotactic radiosurgery will be performed prior to chemotherapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer meeting the following criteria:&#xD;
&#xD;
               -  One to 3 brain metastases, meeting the following criteria:&#xD;
&#xD;
                    -  No larger than 3 cm&#xD;
&#xD;
                    -  Greater than 5 mm from the optic apparatus&#xD;
&#xD;
                    -  Not involving the brainstem, pons, medulla, or midbrain&#xD;
&#xD;
               -  Stable systemic disease for the past 3 months&#xD;
&#xD;
                    -  Less than 3 months since completion of primary treatment&#xD;
&#xD;
          -  Measurable CNS disease as defined by RECIST criteria&#xD;
&#xD;
          -  No leptomeningeal disease documented by MRI or cerebrospinal fluid cytologic&#xD;
             evaluation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3.0 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  No other malignancy within the past 5 years, except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent major medical illness or psychiatric impairment that, in the&#xD;
             investigator's opinion, would preclude study participation&#xD;
&#xD;
          -  No concurrent active infections&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior complete resection of all brain metastases&#xD;
&#xD;
          -  No prior brain radiation therapy&#xD;
&#xD;
          -  No prior temozolomide or erlotinib hydrochloride&#xD;
&#xD;
          -  No concurrent enzyme-inducing anti-epileptic drugs&#xD;
&#xD;
          -  No concurrent recombinant interleukin-11&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents or therapies,&#xD;
             including chemotherapy, immunotherapy, hormonal cancer therapy, radiation therapy, or&#xD;
             cancer surgery&#xD;
&#xD;
          -  No concurrent enrollment on another clinical trial&#xD;
&#xD;
          -  Surgery for symptomatic brain lesions prior to radiosurgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Molly Gabel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

